IM96 CAR-T Cells
Phase 1Cell therapy
IM96 CAR-T Cells is one of 97 biologic programs targeting Adenocarcinoma. It is currently in Phase 1.
2
Indications
3
Total Trials
2
Active Trials
96
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
268 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Fudr
PfizerPhase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Botensilimab
AAgenus Inc.
Phase 3
Zanzalintinib
Merck & Co.Phase 3
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Phase 3
Cadonilimab
SShanghai Pharmaceuticals Holding Co., Ltd
Phase 3
Leucovorin and 5-FU
AAkeso
Phase 3
Mfolfoxiri Plus Bevacizumab
FFudan University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Digestive System Neoplasm1 trial
Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
Unknown status·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT05287165·19 enrolled
Adenocarcinoma1 trial
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction
Not yet recruiting·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT07406984·18 enrolled
Colorectal Cancer1 trial
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer
Recruiting·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT06718738·9 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IM96 CAR-T Cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details